OBJECTIVE: @entity6 ( @entity6 ) is associated to @entity409 , reducing @entity842 (NO)-dependent vasodilation and increasing production of pro-inflammatory factors, leading to increased long-term cardiovascular risk. Since the effects of phosphodiesterase-5 inhibitors (PDE5i) on endothelial function have not been systematically investigated, we conducted a meta-analysis of available randomised clinical trials (RCTs). DESIGN: A thorough search of the literature was carried out. Relevant studies were considered according to RCT study design, enrolment of @entity1 with Type 2 @entity6 , chronic administration of PDE5i and evaluation of endothelial function through both hemodynamic and endothelial inflammation-related parameters. RESULTS: 15 studies fulfilled the eligibility criteria but only 6 RCTs met the inclusion criteria and were analysed for 476 @entity6 @entity1 , 239 randomized to @entity7855 and 237 to placebo, respectively. Four RCTs evaluated @entity384 ( @entity384 ), demonstrating a weighted mean increase of 2.19% (CI95%: 0.48-3.90). This result showed a high heterogeneity (I2:98%). Thus, a further sub-group meta-analysis was performed, excluding one study through funnel plot. This analysis confirmed a significant, @entity7855 -related @entity384 improvement. @entity7855 improved @entity2232 and high sensitivity C-reactive protein of about -0.94pg/mL and -0.36mg/L, respectively, not reaching statistical significance (p=0.69 and p=0.22, respectively). Finally, @entity7855 administration significantly reduced @entity650 ( @entity650 ) serum levels (-0.82 pg/mL; CI95%:-1.58 to -0.07). CONCLUSION: This meta-analysis suggests a beneficial effect of chronic PDE5i administration on endothelial function. Chronic @entity7855 administration seems to improve hemodynamic ( @entity384 ), and serum pro-inflammatory makers ( @entity650 ) in @entity6 @entity1 . Larger studies are needed to confirm the effects of chronic PDE5i on endothelial function.

THERAPY OF ENDOCRINE DISEASE: Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in XXXX : a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['men'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'Diabetes mellitus', 'DM'] @entity2232 :: ('1906', 'Gene') :: ['endothelin(ET)-1'] @entity384 :: ('MESH:D002311', 'Disease') :: ['flow-mediated dilation', 'FMD'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity7855 :: ('MESH:C101426', 'Chemical') :: ['Sildenafil'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']
@entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']
